Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.96−0.10 (-1.24%)
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
Novavax cash
Cash and short-term investments held at the end of each period.
Novavax's cash was $719.34M at Jun 30, 2026. For fiscal 2025 it was $735.08M, down 21.6% from the year before. Over ten years it grew 8.8% a year on average. The highest annual figure on record is $1.53B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $735.08M | -21.6% |
| FY2024 | Dec 31, 2024 | $938.18M | +65.0% |
| FY2023 | Dec 31, 2023 | $568.51M | -57.9% |
| FY2022 | Dec 31, 2022 | $1.35B | -11.7% |
| FY2021 | Dec 31, 2021 | $1.53B | +89.5% |
| FY2020 | Dec 31, 2020 | $806.39M | +881.2% |
| FY2019 | Dec 31, 2019 | $82.18M | -20.9% |
| FY2018 | Dec 31, 2018 | $103.94M | -44.2% |
| FY2017 | Dec 31, 2017 | $186.43M | -31.1% |
| FY2016 | Dec 31, 2016 | $270.38M | -14.7% |
| FY2015 | Dec 31, 2015 | $316.81M | +88.5% |
| FY2014 | Dec 31, 2014 | $168.06M | +26.3% |
| FY2013 | Dec 31, 2013 | $133.07M | +664.8% |
| FY2012 | Dec 31, 2012 | $17.40M | +23.4% |
| FY2011 | Dec 31, 2011 | $14.10M | +75.0% |
| FY2010 | Dec 31, 2010 | $8.06M | -79.2% |
| FY2009 | Dec 31, 2009 | $38.76M | +43.9% |
| FY2008 | Dec 31, 2008 | $26.94M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $719.34M | +14.6% |
| Q1 FY2026 | Mar 31, 2026 | $790.33M | +5.9% |
| Q4 FY2025 | Dec 31, 2025 | $735.08M | -21.6% |
| Q3 FY2025 | Sep 30, 2025 | $762.89M | -17.5% |
| Q2 FY2025 | Jun 30, 2025 | $627.54M | -41.1% |
| Q1 FY2025 | Mar 31, 2025 | $746.62M | +50.5% |
| Q4 FY2024 | Dec 31, 2024 | $938.18M | +65.0% |
| Q3 FY2024 | Sep 30, 2024 | $924.49M | +38.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.06B | +105.6% |
| Q1 FY2024 | Mar 31, 2024 | $495.94M | -22.1% |
| Q4 FY2023 | Dec 31, 2023 | $568.51M | -57.9% |
| Q3 FY2023 | Sep 30, 2023 | $666.36M | -48.5% |
| Q2 FY2023 | Jun 30, 2023 | $517.94M | -62.7% |
| Q1 FY2023 | Mar 31, 2023 | $636.94M | -59.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.35B | -11.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.29B | -33.6% |
| Q2 FY2022 | Jun 30, 2022 | $1.39B | -34.6% |
| Q1 FY2022 | Mar 31, 2022 | $1.58B | -22.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.53B | +89.5% |
| Q3 FY2021 | Sep 30, 2021 | $1.95B | +240.6% |
| Q2 FY2021 | Jun 30, 2021 | $2.12B | +248.3% |
| Q1 FY2021 | Mar 31, 2021 | $2.03B | +730.2% |
| Q4 FY2020 | Dec 31, 2020 | $806.39M | +881.2% |
| Q3 FY2020 | Sep 30, 2020 | $571.60M | +652.8% |
| Q2 FY2020 | Jun 30, 2020 | $609.48M | +679.0% |
| Q1 FY2020 | Mar 31, 2020 | $244.67M | +125.1% |
| Q4 FY2019 | Dec 31, 2019 | $82.18M | -20.9% |
| Q3 FY2019 | Sep 30, 2019 | $75.93M | -47.9% |
| Q2 FY2019 | Jun 30, 2019 | $78.24M | -56.1% |
| Q1 FY2019 | Mar 31, 2019 | $108.68M | -33.8% |
| Q4 FY2018 | Dec 31, 2018 | $103.94M | -44.2% |
| Q3 FY2018 | Sep 30, 2018 | $145.65M | -15.6% |
| Q2 FY2018 | Jun 30, 2018 | $178.20M | -4.9% |
| Q1 FY2018 | Mar 31, 2018 | $164.20M | -22.3% |
| Q4 FY2017 | Dec 31, 2017 | $186.43M | -31.1% |
| Q3 FY2017 | Sep 30, 2017 | $172.60M | -42.5% |
| Q2 FY2017 | Jun 30, 2017 | $187.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $211.20M | – |
| Q4 FY2016 | Dec 31, 2016 | $270.38M | – |
| Q3 FY2016 | Sep 30, 2016 | $300.28M | – |
See a number that looks wrong?